Crystagen
Not FDA approvedShort peptide bioregulator
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Crystagen is a synthetic short peptide from the Russian bioregulator line associated with Vladimir Khavinson's research group, commonly described as a tripeptide (reported as Glu-Asp-Pro) marketed for immune system support. It is proposed to act by interacting with DNA or gene regulatory regions to influence gene expression in immune cells, but this mechanism has not been clearly demonstrated.
What the evidence shows
There are no registered human clinical trials and only about one indexed published paper, mostly from laboratory work by the originating research group. No benefit in humans has been established, and its exact composition and effects are unclear from public databases.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.